Trial · NCT06017141
Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study
NCT06017141, Phase 2, Unknown, University of Kansas Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study. Trials, record NCT06017141. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06017141
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study
- NCT number
- NCT06017141
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 80 participants, estimated
- Lead sponsor
- University of Kansas Medical Center
- Conditions
- Colon Adenocarcinoma
- Interventions
- Biospecimen Collection, Electronic Health Record Review, Fentanyl Citrate, Propofol, Questionnaire Administration, Sevoflurane, Surgical Procedure
- First posted
- 2023-08-30
- Last updated
- 2023-08-30
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Neutrophil extracellular traps (NET) formation | Post-operative day (POD) 1 to POD 6 months | The Neutrophil extracellular traps (NET) formation will be assessed by DNA complexes in myeloperoxidase (MPO). MPO are enzymes that come from white blood cells. The level of these enzymes will be compared by study group using statistical models. The time you are under anesthesia, the amount of anesthesia you are given, the type of surgery you have are all variables that will be considered when evaluating the two types of anesthesia. |
| Secondary | Early post-operative recovery | Post-Operative Day 0 to post-operative discharge, approximately 2-4 days | The QoR-40 is a recovery-specific and patient-rated questionnaire that contains 40 items measuring five dimensions: the physical comfort (12 items), emotional state (nine items), physical independence (five items), psychological support (seven items) and pain (seven items). Recovery will be assessed starting at Post-Operative Day Zero until the time you are discharged from the hospital. |
| Secondary | Global and post-operative recovery | Post-Operative Day 0 to 6 months post-operatively | The QoR-40 is a recovery-specific and patient-rated questionnaire that contains 40 items measuring five dimensions: the physical comfort (12 items), emotional state (nine items), physical independence (five items), psychological support (seven items) and pain (seven items). Recovery will be assessed starting at Post-Operative Day Zero, Day One Post-Operative, Day Three Post Operative, Week Three Post-Operative, Week Six Post-Operative, Month Three Post-Operative, and Month Six Post-Operative. |
| Secondary | Post-operative nausea scores | Post-Operative Day 0 to post-operative discharge, approximately 2-4 days | The post operative nausea scores will be assessed using standardized nursing assessments captured in the patient's medical record. These scores will be evaluated starting at Post-Operative Day Zero until patient discharge from the hospital. |
| Secondary | Number and cumulative amount of doses of anti-emetics | Post-Operative Day 0 to post-operative discharge, approximately 2-4 days | The number and amount of doses of antiemetics will be assessed in the patient's medical record starting at Post-Operative Day Zero until the time they are discharged from the hospital. |
| Secondary | Total hospital opioid use | Post-Operative Day 0 to post-operative discharge, approximately 2-4 days | The patient's total opioid use will be assessed in the patient's medical record starting at Post-Operative Day Zero until the time they are discharged from the hospital. |
| Secondary | Patient-reported pain scores | Post-Operative Day 0 to post-operative discharge, approximately 2-4 days | The patient's total opioid use will be assessed in the patient's medical record starting at Post-Operative Day Zero until the time they are discharged from the hospital. |
| Secondary | Number of times a pro re nata (PRN) medication administered | Post-Operative Day 0 to post-operative discharge, approximately 2-4 days | The number of times a patient is administered medication PRN (as needed) will be assessed in the patient's medical record starting at Post-Operative Day Zero until the time they are discharged from the hospital. |
| Secondary | First post-op day when participant tolerates a regular diet (at the discretion of the surgical team) | Post-Operative Day 0 to post-operative discharge, approximately 2-4 days | The first day when the patient is able to tolerate a regular diet. This will occur between Post-Operative Day Zero and the time they are discharged from the hospital. |
| Secondary | Time from study entry and from surgery to disease recurrence, death, or loss to follow up | Post-Operative Day 0 up to Five Years Post-Operation | The length of time the patient is on the study and the time from surgery to either the cancer returning, the patient passing away, or the loss contact with the patient starting at Post-Operative Day Zero through the duration on the study (up to five years) unless the patient's disease returns, they pass away, or the study team loses contact with them. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA168524 | The University of Kansas Cancer Center | JENSEN, ROY A. | UNIVERSITY OF KANSAS MEDICAL CENTER | NATIONAL CANCER INSTITUTE | 2012 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06017141
GET https://conductscience.org/api/trials/v1/NCT06017141/registered